Background: Cytologic examination of specimens obtained from the respiratory tract is a
Introduction
Lung cancer is the leading cause of cancer death in developed countries (1) . In patients with suspected lung cancer, a clear diagnosis is mandatory to determine the treatment strategy.
Flexible fiberoptic bronchoscopy is a safe and relatively easy procedure that has proved extremely useful in the diagnosis and management of many pulmonary diseases (2) . In fact, bronchoscopy can be considered as the primary diagnostic tool in patients with suspected centrally located pulmonary carcinoma. Bronchoscopic procedures for the diagnosis of lung cancer include cytologic examination of specimens from bronchial biopsy, bronchial brushing and bronchial washing/bronchoalveolar lavage. These tests are less invasive than other tissue procurement methods, carry a small risk of complications, and have high specificity. However, sensitivity is relatively low, especially for peripheral lesions that are beyond the visual segmental bronchi (3) . It is expected that new approaches, such as the detection of molecular markers, could be used in the future to enhance the sensitivity of cytologic examination in the diagnosis of bronchial fluids. In fact, some molecular markers have already been shown to be differentially increased in bronchial fluids from lung cancer patients. These include: proteins, such as carcinoembryonic antigen, tumor polypeptide antigen, neuro-specific enolase or telomerase (4-7); cell-free nucleic acids (8-10); chromosome and locus-specific changes (11) (12) (13) (14) ; and epigenetic modifications (15, 16) . We have previously reported that complement factor H is expressed and secreted by many non-small cell lung cancer (NSCLC) tumors (17) .
Factor H is an inhibitor of complement activation and promotes tumor growth in vivo (18).
The aim of the present study was to explore whether factor H levels were detectable in bronchial fluids of lung cancer patients, and to evaluate its potential diagnostic usefulness. Our results demonstrate that bronchoalveolar lavage fluids from subjects with lung cancer present
Materials and Methods

Patients
Seventy eight subjects undergoing diagnostic bronchoscopy at the Clinica Universidad de Navarra were consecutively included in the study. Based on the diagnosis, bronchoalveolar lavage samples were divided into four groups (Supplement Table S1 ): samples from patients with non-malignant lung disease (group I), samples from patients with lung malignancies in which the cytologic examination of the bronchoalveolar lavage revealed malignant cells (group II), samples from patients with centrally located, endoscopically visible, lung malignancies in which cytologic examination of the bronchoalveolar lavage did not revealed malignant cells (group III), and samples from patients with peripheral, non-visible, lung malignancies in which malignant cells were not identified (group IV). Table 1 Germany). For the determination of albumin, prior to the assay, bronchoalveolar lavage and sputum samples were diluted 1:1000 and 1:100, respectively, in phosphate buffered saline: 10 mM phosphate, 150 mM NaCl, pH 7.4. For hemoglobin determination, bronchoalveolar lavage samples were diluted 1:10. Total protein was determined using the BCA protein assay (Pierce, Rockford, IL), with bovine serum albumin as the standard.
Statistical analysis
Box plots were used to present the results. In these plots, the bottom and top of the boxes represent the lower and upper quartiles, the band inside the box is the median, and the whiskers the minimum and maximum of all the data. SPSS 15.0 software was used for statistical analysis. The Mann-Whitney U test was used to compare values between lung cancer and control groups. Relationship between variables was quantified using Spearman's rank correlation. Receiver operating characteristic (ROC) curves were used to define the best cut-off points for the diagnostic markers, and to describe and compare their performance. Area under the ROC curve, as well as the 95% confidence interval, was also calculated. A p value of less than 0.05 was considered as statistically significant.
Results
Evaluation of factor H in bronchoalveolar lavage fluids
Quantification of complement factor H was first performed in samples from patients with nonmalignant lung disease (group I in Supplement Table S1 ) and samples from patients with lung malignancies in which the cytologic examination of the bronchoalveolar lavage sample had revealed malignant cells (group II in Supplement Table S1 ). Bronchoalveolar lavage group, no association was found between factor H levels and tumor histology. In fact, both NSCLC and small cell lung cancer (SCLC) patients had high levels of factor H in their bronchoalveolar fluids. We then evaluated the possibility that this protein extravasated from blood to bronchial lumen. For this aim, we examined the concentration of albumin in the clinical samples. There was a significantly higher concentration of albumin in bronchoalveolar lavage samples of the lung cancer group than in those of the control group (p=0.006) ( Table 2 ; p<0.001). These results strongly suggest that lung cancer patients present a significant increase in the concentration of plasma proteins in bronchoalveolar fluids. In fact, there was also a significant increase in the amount of total protein in bronchoalveolar lavage supernatants from patients with lung cancer as compared with the control group (p=0.001). To exclude the presence of blood due to bleeding during the bronchoscopy procedure, the amount of hemoglobin in the samples was determined. Hemoglobin levels were similar between the control group and the lung cancer group (p=0.912) ( Table 2 ). Besides, there was no correlation between factor H and hemoglobin (r=0.210; p=0.219).
A ROC curve was generated for factor H (Fig. 1C) and albumin ( Fig 1D) . Table 3 . Sensitivity and specificity of cytologic examination and the factor H and albumin tests in the bronchoalveolar lavage fluids from the 78 subjects consecutively included in the study
